Evidence map›Paper›PMID 33068398›Full record

ArticleBrain : a journal of neurology2020

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.

Niklas Mattsson-Carlgren, Shorena Janelidze, Sebastian Palmqvist, Nicholas Cullen, Anna L Svenningsson, Olof Strandberg, David Mengel, Dominic M Walsh, Erik Stomrud, Jeffrey L Dage and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain : a journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
233citing papers in PubMed, 4 pooled it
17.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

233 citing papers in PubMed, 4 syntheses or guidelines pooled it, 321 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  6. Trial
  7. Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Excitation-inhibition imbalance links amyloid pathophysiology to cognition in non-demented individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  14. Article
  15. miR-214-3p and NCKAP1: A microglial functional dimension of Alzheimer's progression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

173 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Niklas Mattsson-CarlgrenClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Shorena JanelidzeClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Sebastian PalmqvistClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Nicholas CullenClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Anna L SvenningssonClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Olof StrandbergClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
David MengelLaboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Dominic M WalshLaboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Erik StomrudClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Jeffrey L DageEli Lilly and Company, Indianapolis, IN, USA.
Oskar HanssonClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Lund University · SEBrigham and Women's Hospital · USEli Lilly (United States) · US

Funding

Transgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3M
NIA NIH HHS P01 AG017586
6 · The paper itself

Abstract

Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer's disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (median three samples per person, median time from first to last sample, 4.3 years). Preclinical (amyloid-β-positive cognitively unimpaired, n = 62) and prodromal (amyloid-β-positive mild cognitive impairment, n = 49) Alzheimer's disease had accelerated p-tau217 compared to amyloid-β-negative cognitively unimpaired (β  =  0.56, P < 0.001, using linear mixed effects models) and amyloid-β-negative mild cognitive impairment patients (β  =  0.67, P < 0.001), respectively. Mild cognitive impairment patients who later converted to Alzheimer's disease dementia (n = 40) had accelerated p-tau217 compared to other mild cognitive impairment patients (β  =  0.79, P < 0.001). P-tau217 did not change in amyloid-β-negative participants, or in patients with mild cognitive impairment who did not convert to Alzheimer's disease dementia. For 80% power, 109 participants per arm were required to observe a slope reduction in amyloid-β-positive cognitively unimpaired (71 participants per arm in amyloid-β-positive mild cognitive impairment). Longitudinal increases in p-tau217 correlated with longitudinal worsening of cognition and brain atrophy. In summary, plasma p-tau217 increases during early Alzheimer's disease and can be used to monitor disease progression.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionDisease ProgressionFemaleHumansLongitudinal StudiesMaleMental Status and Dementia TestsMiddle AgedNeuropsychological TestsPhosphorylationProspective StudiesAmyloid beta-PeptidesBiomarkersMAPT protein, humantau ProteinsThreonineAlzheimer’s diseasebiomarkerplasmap-taup-tau217

Identifiers

PMID33068398
PMCPMC7719022
OpenAlexW3092650901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.